Main Article Content



  1. The effectiveness of vaccination through the kinetics of the antibody response to the SARS-COV-2 vaccine administration by examining IgG S-RBD levels was aimed.

  2. Two doses of the Sinovac vaccine formed antibodies in healthy individuals in the first 3rd month after vaccination.

  3. An S-RBD IgG antibody in the 6th-month post-vaccination was significantly different between groups without a history and groups with a history of infection with COVID-19.



Since it was declared a pandemic in early 2020, Coronavirus Disease 2019 (Covid-19) has caused high morbidity and mortality in the world. In view of the urgency of the situation, vaccination efforts are needed to break the chain of disease transmission. Various types of vaccines have been successfully developed and obtained approval for emergency use. However, the effectiveness of these vaccines, both in the short and long term, has not been fully known. This study aimed to examine the effectiveness of vaccination through the kinetics of the antibody response to the administration of the SARS-COV-2 vaccine by examining IgG S-RBD levels. This study was an observational analytic study with a prospective cohort approach carried out between January and November 2021 at Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. Fifty health workers who received Sinovac vaccination in as many as 2 doses underwent venous blood taking and measurement of quantitative S-RBD antibody level. Then, quantitative S-RBD IgG antibody levels were measured and recorded in each subject. The mean S-RBD IgG antibody was found to have fluctuation. The titer was found to significantly increase on day 14 and dropped significantly in month 3 (p <0.001). There was a significant difference in S-RBD IgG levels 6 months after vaccination between Covid-19 uninfected groups and Covid-19 infected groups (p <0.001). In a conclusion, two doses of the Sinovac vaccine formed antibodies, although humoral immunity obtained tended to decrease in 3rd month after vaccination to healthy individuals. The average level of S-RBD IgG antibody in the sixth month post-vaccination was found to be significantly different between groups without history and groups with a history of with infection COVID-19.


Sinovac vaccination covid-19 IgG S-RBD kinetics virus coronavirus

Article Details

How to Cite
Nugraha, J., Permatasari, C. A. ., & Fitriah, M. (2022). Durability of S-RBD IgG Antibody Levels after Sinovac Vaccination in Healthcare Workers. Folia Medica Indonesiana, 58(3), 234–241.


  1. Amanat F, Stadlbauer D, Strohmeier S, et al (2020). A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033–1036.
  2. Azkur A, Akdis M, Azkur D, et al (2020). Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy Eur. J. Allergy Clin. Immunol. 75, 1564–1581.
  3. Bratcher-Bowman N (2021). Convalescent Plasma EUA Letter of Authorization. Available from Accessed March 23, 2021.
  4. Goel R, Painter M, Apostolidis S, et al (2021). mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science 374, 1–19.
  5. Hall V, Foulkes S, Charlett A, et al (2021). SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: A large, multicentre, prospective cohort study (SIREN). Lancet 397, 1459–1469.
  6. Hamady A, Lee J, Loboda Z (2022). Waning antibody responses in COVID-19: What can we learn from the analysis of other coronaviruses? Infection 50, 11–25.
  7. Ministry of Health (2020). Pedoman pencegahan dan pengendalian COVID-19. Jakarta, Indonesia.
  8. Jin Y, Yang H, Ji W, et al (2020). Virology, epidemiology, pathogenesis, and control of covid-19. Viruses 12, 1–17.
  9. Liu Z, Xu W, Xia S, et al (2020). RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct. Target. Ther. 5, 1–10.
  10. Lozano-Ojalvo D, Camara C, Lopez-Granados E, et al (2021). Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals. Cell Rep. 36, 1–8.
  11. Natarajan H, Crowley A, Butler S, et al (2021). Markers of polyfunctional SARS-CoV-2 antibodies in convalescent plasma. MBio 12, 1–14.
  12. Nile S, Nile A, Qiu J, et al (2020). COVID-19: Pathogenesis, cytokine storm, and therapeutic potential of interferons. Cytokine Growth Factor Rev. 53, 66–70.
  13. Ontañón J, Blas J, de Cabo C, et al (2021). Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response. EBioMedicine 73, 1–5.
  14. World Health Organization (2020). COVID 19 public health emergency of international concern (PHEIC) global research and innovation forum: Towards a research roadmap. Geneva.
  15. Prekumar L, Segovia-Chumbez B, Jadi R, et al (2020). The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci. Immunol. 5, 1–14.
  16. Committee for Covid-19 Handling and National Economy Restoration (2021). Data Vaksinasi COVID-19 (Update per 21 Maret 2021). Available from Accessed March 22, 2021.
  17. Terpos E, Trougakos I, Karalis V, et al (2021). Kinetics of anti-SARS-CoV-2 antibody responses 3 months post complete vaccination with BNT162B2; A prospective study in 283 health workers. Cells 10, 1–17.
  18. Trougakos I, Terpos E, Zirou C, et al (2021). Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Med. 19, 1–11.
  19. Xia S, Duan K, Zhang Y, et al (2020). Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials. J. Am. Med. Assoc. 324, 951–960.